Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 4
2014 4
2015 5
2016 6
2017 5
2018 13
2019 15
2020 10
2021 11
2022 6
2023 11
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Raje N, et al. N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Free PMC article. Clinical Trial.
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Gulla A, et al. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. Blood Cancer Discov. 2021. PMID: 34568832 Free PMC article.
Novel Agents in Multiple Myeloma.
Szalat R, Munshi NC. Szalat R, et al. Cancer J. 2019 Jan/Feb;25(1):45-53. doi: 10.1097/PPO.0000000000000355. Cancer J. 2019. PMID: 30694859 Free PMC article. Review.
Genomic heterogeneity in multiple myeloma.
Szalat R, Munshi NC. Szalat R, et al. Curr Opin Genet Dev. 2015 Feb;30:56-65. doi: 10.1016/j.gde.2015.03.008. Epub 2015 May 16. Curr Opin Genet Dev. 2015. PMID: 25982873 Review.
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Ghobrial I, et al. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31023594 Review.
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, Cifric S, Folino P, Vinaixa D, Barello F, Clericuzio C, Favasuli VK, Maisano D, Talluri S, Prabhala R, Bianchi G, Fulciniti M, Wen K, Kurata K, Liu J, Penailillo J, Bragoni A, Sapino A, Richardson PG, Chauhan D, Carrasco RD, Hideshima T, Munshi NC, Anderson KC. Gulla A, et al. Blood. 2024 Jun 20;143(25):2612-2626. doi: 10.1182/blood.2023022777. Blood. 2024. PMID: 38551812
96 results